EUCTR2008-000971-15-GB进行中（未招募）不适用
Evaluation of the effects of chronic treatment with venlafaxine (150 mg) and pregabalin (200 mg) on emotional indices of anxiety and panic induced by breathing carbon dioxide.
niversity of Bristol0 个研究点目标入组 54 人开始时间: 2008年4月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female aged 20 to 45 years, inclusive at randomisation (visit 2).
- •Female participants should be surgically sterile or abstinent or, if sexually active, be practising an effective method of birth control (such as prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; they should have a negative urine pregnancy test at screening (visit 1) and randomisation (visit 2).
- •Acceptable weight as defined by a body mass index (BMI: weight [kg]/height [m] ²) of 18 to 30 kg/m², inclusive.
- •Normotensive with sitting (5 minutes) blood pressure between the range of 100 to 140 mmHg systolic, inclusive, and 60 to 90 mmHg diastolic, inclusive. A participant with blood pressure outside this range may be included only if the study physician judges that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- •Healthy on the basis of a pre-study physical examination, medical history, electrocardiogram, urinalysis dipstick and the laboratory results of blood haematology and biochemistry performed within 6 weeks before randomisation. If the results of haematology or biochemistry testing are not within the laboratory’s reference ranges the participant can be included only if the study physician judges that the deviations are not clinically significant. This should be clearly recorded in the source documents.
- •Non-smoker or light smoker (<5 cigarettes per day).
- •Willing to follow the prohibitions and restrictions as specified in Section 7, Prohibitions and Restrictions.
- •Participant must have signed the informed consent form prior to the first study-related procedure, indicating they understand the purpose of and procedures required for the study and are willing to participate in the study.
- •Those participants willing to participate in the pharmacogenomic components of the study must have confirmed they understand the purpose of the procedures involved and indicated that they are willing to participate by signing the appropriate informed consent form..
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Known or suspected hypersensitivity or intolerance to venlafaxine/pregabalin or any of their excipients.
- •History of alcohol or substance dependence within the last 6 months. Participants must have negative results at screening and at randomisation visit for the urine drug screen and alcohol breath test.
- •Consumption of large amounts of caffeinated drinks (no more than 8 cups of standard caffeinated drinks (tea, instant coffee) or 6 cups of stronger coffee or other drinks containing methlyxantines such as coca cola or Red Bull per day).
- •Relevant history or presence upon clinical examination, of cardiac, ophthalmologic, gastro-intestinal, hepatic, or renal disease or other condition known to increase risk of side effects of venlafaxine or pregabalin.
- •Have a history or presence of neurological or psychiatric conditions (such as stroke, traumatic brain injury, epilepsy, space occupying lesions, multiple sclerosis, Parkinson’s disease, vascular dementia, transient ischemic attack, schizophrenia, major depression, generalised anxiety disorder or panic disorder).
- •History of, or current condition of, migraine headaches.
- •Have received prescribed medication within 14 days prior to randomisation (apart from the contraceptive pill). Participants who have taken prescription medication may still be entered into the study, if, in the opinion of the Investigator, the medication received will not interfere with the study procedures or compromise safety (refer to Section 8, Concomitant Therapy).
- •Have received over-the-counter (OTC) medicine within 48 hours prior to randomisation (apart from paracetamol). Participants who have taken OTC medication may still be entered into the study, if, in the opinion of the Investigator, the medication received will not interfere with the study procedures or compromise safety (refer to Section 8, Concomitant Therapy).
- •Participated in a trial with any drug within 84 days of randomisation (visit 2).
- •If female: are pregnant or are trying to get pregnant or are currently breast feeding.
- •Have a personal or a close family member with a history of panic attacks or severe anxiety disorder.
- •History of claustrophobia.
- •Previous experience of the CO2 procedure within the preceding six months.
- •Current or clinically significant history of asthma.
- •Unable or unwilling to comply with study procedures.
研究者
相似试验
进行中（未招募）
不适用
?The effect of acute and chronic administration of the CCK1 receptor antagonist Dexloxiglumide (CR2017) on 24-h pH metry, LES motor and symptoms? pattern, in patients with gastroesophageal reflux disease (GERD). A randomized, double-blind, placebo controlled study? - NDgastroesaphageal reflux disease (GERD)MedDRA version: 9.1Level: LLTClassification code 10017885Term: Gastrooesophageal reflux diseaseEUCTR2007-003478-25-ITROTTAPHARM / ROTTA RESEARCH LABORATORIUM
进行中（未招募）
1 期
A long-term follow-up study for patients treated with Galapagos CAR T cell therapiesRelapsed/refractory B-Cell non-Hodgkin lymphoma, Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Relapsed/refractory multiple myelomaMedDRA version: 21.0Level: LLTClassification code: 10051812Term: Small cell lymphocytic lymphoma Class: 10029104MedDRA version: 20.0Level: HLGTClassification code: 10025320Term: Lymphomas non-Hodgkin's B-cell Class: 10029104MedDRA version: 21.0Level: LLTClassification code: 10008976Term: Chronic lymphocytic leukemia Class: 10029104CTIS2023-510173-34-00Galapagos300
已完成
不适用
A prospective study for the effects of treatment with adalimumab in patients with psoriasis and psoriatic arthritisPsoriatic arthritis, psoriasisSkin and Connective Tissue DiseasesPsoriasisISRCTN23328456Academic Medical Center (AMC) (Netherlands)24
进行中（未招募）
不适用
Study to evaluate the efficacy and safety of bisphosphonates in long term treatment of osteoporosisEUCTR2011-000290-31-DEEvangelisches Krankenhaus Lutherhaus gGmbH
进行中（未招募）
3 期
Comparison of the effect of an ongoing treatment with alendronate or a drug holidayon the fracture risk in osteoporotic patients with a bisphosphonate long term therapyM81M80Osteoporosis without pathological fractureOsteoporosis with pathological fractureDRKS00000721Evangelisches Krankenhaus Lutherhaus gGmbH424